Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention

Table 3 Chemotherapy-induced peripheral neuropathy per cycle, according to Common Terminology Criteria for Adverse Events (version 4.0)

Chemotherapy	Number of patients	Reported CIPN, n (%)
		Grade 0	Grade 1	Grade ≥ 2
Cycle 1	44	44 (100)	0 (0)	0 (0)
Cycle 2	44	43 (97.7)	0 (0)	0 (0)
Cycle 3	43	40 (93.0)	1 (2.3)	0 (0)
Cycle 4	41	33 (80.5)	1 (2.4)	0 (0)
Cycle 5	34	22 (64.7)	1 (2.9)	1 (2.9)
Cycle 6	24	20 (83.3)	2 (8.3)	1 (4.2)

CIPN: Chemotherapy-induced peripheral neuropathy.